Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。